166 related articles for article (PubMed ID: 38215600)
21. A new paradigm of genetic testing for hereditary breast/ovarian cancers.
Kwong A; Chen JW; Shin VY
Hong Kong Med J; 2016 Apr; 22(2):171-7. PubMed ID: 26980575
[TBL] [Abstract][Full Text] [Related]
22. Testing for hereditary breast and ovarian cancer in the southeastern United States.
Miron A; Schildkraut JM; Rimer BK; Winer EP; Sugg Skinner C; Futreal PA; Culler D; Calingaert B; Clark S; Kelly Marcom P; Iglehart JD
Ann Surg; 2000 May; 231(5):624-34. PubMed ID: 10767783
[TBL] [Abstract][Full Text] [Related]
23. Centralisation of services for gynaecological cancer.
Woo YL; Kyrgiou M; Bryant A; Everett T; Dickinson HO
Cochrane Database Syst Rev; 2012 Mar; 2012(3):CD007945. PubMed ID: 22419327
[TBL] [Abstract][Full Text] [Related]
24. Clinical management of women with genomic BRCA1 and BRCA2 mutations.
Chang J; Elledge RM
Breast Cancer Res Treat; 2001 Sep; 69(2):101-13. PubMed ID: 11759816
[TBL] [Abstract][Full Text] [Related]
25. Lynch syndrome for the gynaecologist.
Ryan NA; McMahon RF; Ramchander NC; Seif MW; Evans DG; Crosbie EJ
Obstet Gynaecol; 2021 Jan; 23(1):9-20. PubMed ID: 33679238
[TBL] [Abstract][Full Text] [Related]
26. Hereditary gynecologic cancers.
Mutch D; Denny L; Quinn M;
Int J Gynaecol Obstet; 2014 Mar; 124(3):189-92. PubMed ID: 24429354
[No Abstract] [Full Text] [Related]
27. Phenotypic heterogeneity of hereditary gynecologic cancers: a report from the Creighton hereditary cancer registry.
Casey MJ; Bewtra C; Lynch HT; Snyder C; Stacy M; Watson P
Fam Cancer; 2013 Dec; 12(4):719-40. PubMed ID: 23666231
[TBL] [Abstract][Full Text] [Related]
28. Changing patterns of referral into a family history clinic and detection of ovarian cancer: a retrospective 10-year review.
Smallwood KG; Crockett S; Huang V; Cullimore V; Davies J; Satti G; Phillips A
J Obstet Gynaecol; 2022 Oct; 42(7):2652-2658. PubMed ID: 35980980
[TBL] [Abstract][Full Text] [Related]
29. BRCA1 gene mutations may explain more than 80% of excess number of ovarian cancer cases after breast cancer - a population based study from the Western Sweden Health Care region.
Einbeigi Z; Enerbäck C; Wallgren A; Nordling M; Karlsson P
Acta Oncol; 2010 Apr; 49(3):361-7. PubMed ID: 20151938
[TBL] [Abstract][Full Text] [Related]
30. Genetic testing in Poland and Ukraine: should comprehensive germline testing of
Nguyen-Dumont T; Karpinski P; Sasiadek MM; Akopyan H; Steen JA; Theys D; Hammet F; Tsimiklis H; Park DJ; Pope BJ; Slezak R; Stembalska A; Pesz K; Kitsera N; Siekierzynska A; Southey MC; Myszka A
Genet Res (Camb); 2020 Aug; 102():e6. PubMed ID: 32772980
[TBL] [Abstract][Full Text] [Related]
31. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases.
Pal T; Permuth-Wey J; Betts JA; Krischer JP; Fiorica J; Arango H; LaPolla J; Hoffman M; Martino MA; Wakeley K; Wilbanks G; Nicosia S; Cantor A; Sutphen R
Cancer; 2005 Dec; 104(12):2807-16. PubMed ID: 16284991
[TBL] [Abstract][Full Text] [Related]
32. Awareness of genetic counseling and genetic testing for hereditary gynecologic cancers among Korean healthcare providers: A survey.
Kim M; Cheol Lim M; Ji Nam E; Huang D; Kim S; Jong Yoo H; Lee YY; Chang YJ;
J Genet Couns; 2022 Apr; 31(2):546-553. PubMed ID: 34674340
[TBL] [Abstract][Full Text] [Related]
33. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
Piver MS
Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
[TBL] [Abstract][Full Text] [Related]
34. Prevention and therapy for BRCA1/2 mutation carriers and women at high risk for breast and ovarian cancer.
Kuschel B; Lux MP; Goecke TO; Beckmann MW
Eur J Cancer Prev; 2000 Jun; 9(3):139-50. PubMed ID: 10954253
[TBL] [Abstract][Full Text] [Related]
35. Hereditary ovarian cancers: from BRCA mutations to clinical management. A modern appraisal.
Tinelli A; Malvasi A; Leo G; Vergara D; Pisanò M; Ciccarese M; Chiuri VE; Lorusso V
Cancer Metastasis Rev; 2010 Jun; 29(2):339-50. PubMed ID: 20405170
[TBL] [Abstract][Full Text] [Related]
36. Hereditary Ovarian Cancer: Towards a Cost-Effective Prevention Strategy.
Ghose A; Bolina A; Mahajan I; Raza SA; Clarke M; Pal A; Sanchez E; Rallis KS; Boussios S
Int J Environ Res Public Health; 2022 Sep; 19(19):. PubMed ID: 36231355
[TBL] [Abstract][Full Text] [Related]
37. Population-based screening for breast and ovarian cancer risk due to BRCA1 and BRCA2.
Gabai-Kapara E; Lahad A; Kaufman B; Friedman E; Segev S; Renbaum P; Beeri R; Gal M; Grinshpun-Cohen J; Djemal K; Mandell JB; Lee MK; Beller U; Catane R; King MC; Levy-Lahad E
Proc Natl Acad Sci U S A; 2014 Sep; 111(39):14205-10. PubMed ID: 25192939
[TBL] [Abstract][Full Text] [Related]
38. [Experience at Sheba Hospital in oncogenetic counseling and genetic testing of women with a high risk for breast and ovarian cancer].
Theodor L; Shiri-Sverdlov R; Yechezkel GH; Bar-Sade RB; Gak E; Friedman I; Kruglikova A; Ben-Baruch G; Risel S; Papa MZ; Goldman B; Friedman E
Harefuah; 1998 Apr; 134(8):593-9, 672. PubMed ID: 10911419
[TBL] [Abstract][Full Text] [Related]
39. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada.
Risch HA; McLaughlin JR; Cole DE; Rosen B; Bradley L; Fan I; Tang J; Li S; Zhang S; Shaw PA; Narod SA
J Natl Cancer Inst; 2006 Dec; 98(23):1694-706. PubMed ID: 17148771
[TBL] [Abstract][Full Text] [Related]
40. Ovarian cancer associated with inherited mutations in BRCA1 or BRCA2.
Swisher E
Curr Womens Health Rep; 2003 Feb; 3(1):27-32. PubMed ID: 12521547
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
